A Study of T2000 in Essential Tremor
Information source: Taro Pharmaceuticals USA
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Essential Tremor
Intervention: T2000 (Drug); T2000 (Drug); T2000 (Drug)
Phase: Phase 2
Status: Terminated
Sponsored by: Taro Pharmaceuticals USA Official(s) and/or principal investigator(s):
Anthony Lang, MD FRCPC, Principal Investigator, Affiliation: University Health Network - Toronto Western Hospital
Summary
This study will evaluate the safety and efficacy of T2000 when used to treat patients with
moderate to severe essential tremor over a 20 week period.
Essential tremor (ET) is a common form of involuntary shaking not related to Parkinson's
disease. The medications that are currently used to treat ET work in a small proportion of
patients and provide only partial improvement in symptoms. Use of these current medications
is also limited by side-effects in many patients.
T2000 is a medication currently under development for the treatment of essential tremor.
Although T2000 is a new medication, it belongs to a class of medications that has been used
for many years for the treatment of a variety of medical conditions. In previous studies,
T2000 appeared to be effective in controlling symptoms of ET and some patients with severe ET
had major improvements in tremor. T2000 was well tolerated for periods up to 20 days and
the minimal side-effects seen were those that would be expected for medications in this
class.
The current study will evaluate the safety and efficacy of T2000 in patients with moderate to
severe essential tremor. Patients will receive doses of T2000 beginning at 600 mg a day,
followed by 800 mg a day and up to 1000 mg a day. The total duration of treatment will be 20
weeks. Patient's tremor and neurological examination will be monitored throughout the study.
The response to T2000 will be determined by comparing the severity of tremor while patients
are receiving T2000 compared to the tremor observed without active medication.
Clinical Details
Official title: Phase II Efficacy and Safety of Taro Pharmaceuticals' Pro-Drug T2000 (1,3-Dimethoxymethyl-5,5-Diphenyl-Barbituric Acid) In Patients With Essential Tremor: A Randomized, Double-Blind, Placebo-Controlled, Sequential Dose Escalation Study
Study design: Treatment, Randomized, Double Blind (Subject, Investigator), Dose Comparison, Parallel Assignment, Efficacy Study
Primary outcome: Effect of treatment on tremor will be measured by a tremor scale as well as by assessment of functional activity with specific tasks. Patients receiving active treatment will be compared to placebo at 2 months of treatment.Response at various dosages will be compared to baseline for all patients.
Secondary outcome: Safety parameters including neurological examination, blood tests and EKG will be monitored throughout the treatment period and during withdrawal of the medication.
Eligibility
Minimum age: 18 Years.
Maximum age: 75 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Confirmed essential tremor by NIH criteria
- Significant functional activity limitation due to ET
- Patients who have failed, are inadequately treated or cannot tolerate alternative
treatments for ET as well as treatment naïve patients who have considered but
declined alternative treatment
Exclusion Criteria:
- Patients adequately controlled without side effects on a current ET treatment
- Pregnant patients or patients who may become pregnant during the study
- Patients with other medical conditions that may cause tremor, such as Parkinson's
disease or active hyperthyroidism
- Patients taking medications that might produce tremor or interfere with the evaluation
of tremor such as CNS-stimulants or beta-blockers
- Patients who must take medications that alter liver metabolism as well as patients
with liver disease or coagulation disorders
- Patients with seizure disorders
- Patients with a history of allergy or hypersensitivity reaction to barbiturates or
other related medications, such as phenobarbital or phenytoin
- Patient with significant general medical or clinical laboratory abnormalities
Locations and Contacts
Movement Disorder Clinic: University Health Network; Toronto Western Hospital, Toronto, Ontario M5R 2N5, Canada
Parkinson's Disease and Movement Disorders Clinic - The Ottawa Hospital: Civic Campus, Ottawa, Ontario K1Y 4E9, Canada
London Health Sciences Center, London, Ontario N6A 5A5, Canada
Additional Information
Starting date: August 2006
Ending date: December 2007
Last updated: April 3, 2008
|
